El Hamaky et al. designed and synthesized quinazoline‐1,2,3‐triazole hybrids 65 as multitarget EGFR, VEGFR‐2, and Topo II inhibitors tested them anticancer activity against HeLa, HePG‐2, MCF‐7, and HCT‐116 cancer cell lines. This evidence concerns the gene KDR and cancer.